Microdosing of LSD does not show efficacy in adults with ADHD
The Brown University Psychopharmacology Update July 1, 2025 DOI: 10.1002/pu.31324
Summary
AI-generated from the abstractA Phase 2A trial found that microdosing LSD over six weeks did not significantly reduce ADHD symptoms in adults compared to placebo. Both the LSD and placebo groups showed marked improvement, indicating no added benefit from the drug.
Study at a glance
| Characteristics | Phase 2A trial Peer reviewed |
|---|---|
| Population | Adults with attention-deficit hyperactivity disorder (ADHD) |
| Intervention | LSD |
| Duration | 6-week intervention |
| Key finding | Microdosing LSD over six weeks showed no significant benefits over placebo in reducing ADHD symptoms in adults. |
Abstract
Microdosing of lysergic acid diethylamide (LSD) over a 6‐week period showed no significant benefits over placebo in reducing symptoms of attention‐deficit hyperactivity disorder (ADHD) in adults, a Phase 2A trial has found. Both the LSD and placebo groups experienced marked improvement, the investigators reported.